NW BioがASCOのIndustry Theater Sessionで第3相試験暫定データを議論へ

AsiaNet 73800 （0971）

【ベセスダ（メリーランド州）2018年6月1日PR Newswire＝共同通信JBN】固形腫瘍がん治療用のパーソナライズされた免疫療法DCVax（R）を開発しているバイオテクノロジー企業であるNorthwest Biotherapeutics （OTCQB: NWBO）（NW Bio）は、同社最高技術責任者（CTO）であるマーミック・L・ボシュ博士が6月3日（日）午後4時15分（米中部時間）にイリノイ州シカゴのMcCormick Place Convention Centerで開催されるASCO Conference（米がん治療学会総会）のIndustry Expert Theater内のExhibit Hallで、新たに診断された膠芽細胞腫脳腫瘍に対する同社のDCVax（R）-Lの第3相試験から5月29日に発表された暫定データについて議論すると発表した。

さらに、時間が許せば、特定の医師および長期生存患者は、DCVax-Lに関する彼らの個人的経験を述べる可能性もある。

ボッシュ博士によるプレゼンテーションではウェブキャストが準備中である。準備が完了した時点で詳細は、当社のウェブサイト（www.nwbio.com ）の「最新のプレゼンテーション」の見出しの下に掲載される。ウェブキャストは、当社のウェブサイト上でのプレゼンテーションの後にレビュー目的で供される予定。このプレゼンテーションは、2018 ASCO年次総会の公式プレゼンテーションではない。このプレゼンテーションは、ASCOまたはConquer Cancer Foundationにより主催、承認、認定されてない。CMEが認定したものではない。

▽Northwest Biotherapeuticsについて

Northwest Biotherapeuticsは、現在の治療よりも効果的にがんを治療するために設計されたパーソナライズされた免疫療法製品の開発に重点を置いたバイオテクノロジー企業である。この製品は化学療法に随伴するような毒性はなく、北米と欧州の両方でコスト効率が良い。同社は、DCVax（R）樹状細胞ベースのワクチンのための広範なプラットフォーム技術を有している。同社のリードプログラムは、新たに診断された多形性膠芽腫（GBM）における患者331人を対象とした第3相試験である。GBMは脳腫瘍の最も攻撃的で致死的な形態であり、「奇病」である。同社はまた、すべてのタイプの手術不能な固形腫瘍がんのためのDCVax-Directによる第1/2相試験を実施中である。同社は患者40人を対象とした第1相試験を完了し、第2相試験の準備を進めている。同社は過去に、転移性卵巣がんのためのDCVax-Lによる第1/2相試験をペンシルベニア大学と共同で実施した。

ソース：Northwest Biotherapeutics

▽問い合わせ先  

Les Goldman

+1-202-841-7909

lgoldman@nwbio.com

NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

PR73800

BETHESDA, Md., June 1, 2018 /PRNewswire=KYODO JBN/ --

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company

developing DCVax(R) personalized immune therapies for solid tumor cancers,

announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry

Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick

Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief

Technical Officer of NW Bio, will discuss the interim data that was published

on May 29 from the Company's Phase 3 trial of DCVax(R)-L for newly diagnosed

Glioblastoma brain cancer.

In addition, if time permits, certain physicians and long-term survivor

patients may describe their personal experiences with DCVax-L.

Arrangements are being made for Dr. Bosch's presentation to be webcast.  

Details will be posted on the Company's website (www.nwbio.com) under the

heading "Most Recent Presentations" when the arrangements are completed.  It is

anticipated that the webcast will be available for review after the

presentation on the Company's website.  This presentation is not an official

presentation of the 2018 ASCO Annual Meeting.  It is not sponsored, endorsed,

or accredited by ASCO or the Conquer Cancer Foundation. Not CME-accredited.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing

personalized immunotherapy products designed to treat cancers more effectively

than current treatments, without toxicities of the kind associated with

chemotherapies, and on a cost-effective basis, in both North America and

Europe.  The Company has a broad platform technology for DCVax(R) dendritic

cell-based vaccines.  The Company's lead program is a 331-patient Phase III

trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most

aggressive and lethal form of brain cancer, and is an "orphan disease."  The

Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of

inoperable solid tumor cancers.  It has completed the 40-patient Phase I

portion of the trial, and is preparing for the Phase II portion.  The Company

previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian

cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including

statements concerning future treatment of patients using DCVax and future

clinical trials, are forward-looking statements within the meaning of the

Private Securities Litigation Reform Act of 1995.  Words such as "expect,"

"believe," "intend," "design," "plan," "continue," "may," "will," "anticipate,"

and similar expressions are intended to identify forward-looking statements.  

Actual results may differ materially from those projected in any

forward-looking statement.  Specifically, there are a number of important

factors that could cause actual results to differ materially from those

anticipated, such as risks related to the Company's ability to complete its

clinical trials on a timely basis, uncertainties about the clinical trials

process, uncertainties about the timely performance of third parties, risks

related to whether the Company's products will demonstrate safety and efficacy,

risks related to the Company's ongoing ability to raise additional capital, and

other risks included in the Company's Securities and Exchange Commission

("SEC") filings.  Additional information on the foregoing risk factors and

other factors, including Risk Factors, which could affect the Company's

results, is included in its SEC filings.  Finally, there may be other factors

not mentioned above or included in the Company's SEC filings that may cause

actual results to differ materially from those projected in any forward-looking

statement.  You should not place undue reliance on any forward-looking

statements.  The Company assumes no obligation to update any forward-looking

statements as a result of new information, future events or developments,

except as required by securities laws.

SOURCE  Northwest Biotherapeutics

CONTACT: Les Goldman, +1-202-841-7909, lgoldman@nwbio.com